The vascular endothelium in diabetes - A therapeutic target?

Reviews in Endocrine and Metabolic Disorders

Volumn 14, Issue 1, 2013, Pages 87-99

  Mather, Kieren J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Endothelin; Endothelium; Insulin; Nitric oxide; Therapy; Vasodilation

Indexed keywords

ACIPIMOX; ADVANCED GLYCATION END PRODUCT; ALPHA GLUCOSIDASE INHIBITOR; BENFOTIAMINE; CATECHOL METHYLTRANSFERASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPIGALLOCATECHIN GALLATE; FISH OIL; GEMFIBROZIL; INSULIN SENSITIZING AGENT; METFORMIN; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NICOTINIC ACID; PIOGLITAZONE; PRASTERONE; RESVERATROL;

BLOOD VESSEL TONE; CARDIOVASCULAR RISK; DIABETES MELLITUS; HUMAN; HYPEREMIA; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; REVIEW; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; DIABETES MELLITUS; ENDOTHELINS; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE;

EID: 84874662738     PISSN: 13899155     EISSN: 15732606     Source Type: Journal    
DOI: 10.1007/s11154-013-9237-9     Document Type: Review

References (194)

1. Baron AD, Clark MG. Role of blood flow in the regulation of muscle glucose uptake. Annu Rev Nutr. 1997;17:487-99. (Pubitemid 27328810)
2. Baron AD, Tarshoby M, Hook G, Lazaridis EN, Cronin J, Johnson A, et al. Interaction between insulin sensitivity and muscle perfusion on glucose uptake in human skeletal muscle: evidence for capillary recruitment. Diabetes. 2000;49(5):768-74. (Pubitemid 30339992)
3. Tack CJ, Ong MK, Lutterman JA, Smits P. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone. Diabetologia. 1998;41(5):569-76. (Pubitemid 28206828)
4. Barrett EJ, Eggleston EM, Inyard AC, Wang H, Li G, Chai W, et al. The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia. 2009;52(5):752-64.
5. Cleland SJ, Petrie JR, Ueda S, Elliott HL, Connell JM. Insulin as a vascular hormone: implications for the pathophysiology of cardiovascular disease. Clin Exp Pharmacol Physiol. 1998;25(3-4):175-84. (Pubitemid 28162280)
6. Hsueh WA, Law RE. Insulin signaling in the arterial wall. Am J Cardiol. 1999;84(1A):21J-4J. (Pubitemid 29334856)
7. Montagnani M, Ravichandran LV, Chen H, Esposito DL, Quon MJ. Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells. Mol Endocrinol. 2002;16(8):1931-42. (Pubitemid 34828099)
8. Vincent MA, Montagnani M, Quon MJ. Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium. Curr Diabetes Rep. 2003;3(4):279-88. (Pubitemid 38906783)
9. Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000;101(13):1539-45. (Pubitemid 30180890)
10. Mather K, Anderson TJ, Verma S. Insulin action in the vasculature: physiology and pathophysiology. J Vasc Res. 2001;38(5):415-22. (Pubitemid 34701454)
11. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev. 2007;28(5):463-91. (Pubitemid 47236334)
12. Rattigan S, Barrett EJ, Clark MG. Insulin-mediated capillary recruitment in skeletal muscle: is this a mediator of insulin action on glucose metabolism? Curr Diabetes Rep. 2003;3(3):195-200. (Pubitemid 38906772)
13. Clerk LH, Vincent MA, Lindner JR, Clark MG, Rattigan S, Barrett EJ. The vasodilatory actions of insulin on resistance and terminal arterioles and their impact on muscle glucose uptake. Diabetes Metabol Res Rev. 2004;20(1):3-12. (Pubitemid 38196244)
14. Vincent MA, Clerk LH, Rattigan S, Clark MG, Barrett EJ. Active role for the vasculature in the delivery of insulin to skeletal muscle. Clin Exp Pharmacol Physiol. 2005;32(4):302-7. (Pubitemid 40586066)
15. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Investig. 1994;94(6):2511-5. (Pubitemid 24379629)
16. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Investig. 1994;94(3):1172-9.
17. Cleland SJ, Petrie JR, Small M, Elliott HL, Connell JM. Insulin action is associated with endothelial function in hypertension and type 2 diabetes. Hypertension. 2000;35(1 Pt 2):507-11. (Pubitemid 30054225)
18. Barrett EJ, Wang H, Upchurch CT, Liu Z. Insulin regulates its own delivery to skeletal muscle by feed-forward actions on the vasculature. Am J Physiol Endocrinol Metab. 2011;301(2):E252-63.
19. Kimura K, Tsuda K, Baba A, Kawabe T, Boh-oka S, Ibata M, et al. Involvement of nitric oxide in endothelium-dependent arterial relaxation by leptin. Biochem Biophys Res Commun. 2000;273(2):745-9. (Pubitemid 30599054)
20. Benkhoff S, Loot AE, Pierson I, Sturza A, Kohlstedt K, Fleming I, et al. Leptin potentiates endothelium-dependent relaxation by inducing endothelial expression of neuronal NO synthase. Arterioscler Thromb Vasc Biol. 2012;32(7):1605-12.
21. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003;278(45):45021-6. (Pubitemid 37377262)
22. Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H, et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension. 2003;42(3):231-4. (Pubitemid 37093465)
23. Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahren B, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287(6):E1209-15. (Pubitemid 39491964)
24. Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab. 2007;293(5):E1289-95. (Pubitemid 350106596)
25. Ceriello A, Esposito K, Testa R, Bonfigli AR, Marra M, Giugliano D. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes. Diabetes Care. 2011;34(3):697-702.
26. Esper RJ, Vilarino JO, Machado RA, Paragano A. Endothelial dysfunction in normal and abnormal glucose metabolism. Adv Cardiol. 2008;45:17-43.
27. Han KA, Patel Y, Lteif AA, Chisholm R, Mather KJ. Contributions of dysglycaemia, obesity, and insulin resistance to impaired endothelium-dependent vasodilation in humans. Diabetes Metabol Res Rev. 2011;27(4):354-61.
28. Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation. 1998;97(17):1695-701. (Pubitemid 28211418)
29. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol. 1999;34(1):146-54.
30. Vehkavaara S, Makimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki-Jarvinen H. Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2000;20(2):545-50. (Pubitemid 30086115)
31. Joya-Galeana J, Fernandez M, Cervera A, Reyna S, Ghosh S, Triplitt C, et al. Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects. Diabetes Metabol Res Rev. 2011;27(4):373-82.
32. Pistrosch F, Schaper F, Passauer J, Koehler C, Bornstein SR, Hanefeld M. Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes. Horm Metab Res Horm Stoffwechselforschung Horm Metab. 2009;41(2):104-8.
33. Emoto T, Sawada T, Hashimoto M, Kageyama H, Terashita D, Mizoguchi T, et al. Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease. Am J Cardiol. 2012;109(1):42-6.
34. Hiki M, Shimada K, Kiyanagi T, Fukao K, Hirose K, Ohsaka H, et al. Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH). Circ J Off J Jpn Circ Soc. 2010;74(7):1471-8.
35. Chiasson JL. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabet Med J Br Diabet Assoc. 1996;13(3 Suppl 2):S23-4.
36. Matsumoto K, Yano M, Miyake S, Ueki Y, Yamaguchi Y, Akazawa S, et al. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care. 1998;21(2):256-60. (Pubitemid 28079434)
37. Bhartia M, Tahrani AA, Barnett AH. SGLT-2 inhibitors in development for type 2 diabetes treatment. Rev Diabet Stud RDS. 2011;8(3):348-54.
38. Giannarelli R, Aragona M, Coppelli A, Del Prato S. Reducing insulin resistance with metformin: the evidence today. Diabete Metab. 2003;29(4 Pt 2):6S28-35. (Pubitemid 37187088)
39. Radziuk J, Bailey CJ, Wiernsperger NF, Yudkin JS. Metformin and its liver targets in the treatment of type 2 diabetes. Curr Drug Targets Immune Endocr Metab Disord. 2003;3(2):151-69.
40. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 2001;37(5):1344-50. (Pubitemid 32295597)
41. Diamanti-Kandarakis E, Alexandraki K, Protogerou A, Piperi C, Papamichael C, Aessopos A, et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol Eur Fed Endocr Soc. 2005;152(5):749-56. (Pubitemid 40744544)
42. Vitale C, Mercuro G, Cornoldi A, Fini M, Volterrani M, Rosano GM. Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med. 2005;258(3):250-6. (Pubitemid 41243057)
43. de Aguiar LG, Bahia LR, Villela N, Laflor C, Sicuro F, Wiernsperger N, et al. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care. 2006;29(5):1083-9. (Pubitemid 44115248)
44. Natali A, Baldeweg S, Toschi E, Capaldo B, Barbaro D, Gastaldelli A, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care. 2004;27(6):1349-57. (Pubitemid 38679982)
45. Naka KK, Papathanassiou K, Bechlioulis A, Pappas K, Kazakos N, Kanioglou C, et al. Effects of pioglitazone and metformin on vascular endothelial function in patients with type 2 diabetes treated with sulfonylureas. Diabetes Vasc Dis Res Off J Int Soc Diabetes Vasc Dis. 2012;9(1):52-8.
46. Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. Drugs. 2002;62(10):1463-80. (Pubitemid 34804155)
47. Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care. 2004;27(2):484-90. (Pubitemid 38174076)
48. Watanabe Y, Sunayama S, Shimada K, Sawano M, Hoshi S, Iwama Y, et al. Troglitazone improves endothelial dysfunction in patients with insulin resistance. J Atheroscler Thromb. 2000;7(3):159-63.
49. Caballero AE, Saouaf R, Lim SC, Hamdy O, Abou-Elenin K, O'Connor C, et al. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metab Clin Exp. 2003;52(2):173-80. (Pubitemid 36388839)
50. Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol. 2004;93(3):362-5. (Pubitemid 38167440)
51. Forst T, Lubben G, Hohberg C, Kann P, Sachara C, Gottschall V, et al. Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. Microcirculation. 2005;12(7):543-50. (Pubitemid 41632173)
52. Martens FM, Visseren FL, de Koning EJ, Rabelink TJ. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol. 2005;46(6):773-8. (Pubitemid 44378249)
53. Tsuchiya K, Akaza I, Yoshimoto T, Hirata Y. Pioglitazone improves endothelial function with increased adiponectin and high-density lipoprotein cholesterol levels in type 2 diabetes. Endocr J. 2009;56(5):691-8.
54. Esposito K, Ciotola M, Carleo D, Schisano B, Saccomanno F, Sasso FC, et al. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care. 2006;29(5):1071-6. (Pubitemid 44115246)
55. Goya K, Sumitani S, Otsuki M, Xu X, Yamamoto H, Kurebayashi S, et al. The thiazolidinedione drug troglitazone up-regulates nitric oxide synthase expression in vascular endothelial cells. J Diabetes Complications. 2006;20(5):336-42. (Pubitemid 44292533)
56. Wang CH, Ting MK, Verma S, Kuo LT, Yang NI, Hsieh IC, et al. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. Am Hear J. 2006;152(6):e1051-8. 1051. (Pubitemid 44854808)
57. Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM, Bank AJ. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. Vasc Med. 2007;12(4):311-8.
58. Rudofsky Jr G, Reismann P, Grafe IA, Konrade I, Djuric Z, Tafel J, et al. Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-kappaB binding activity. Horm Metab Res Horm Stoffwechselforschung Horm Metab. 2007;39(9):665-71. (Pubitemid 47492650)
59. Patel SR, Mailloux LM, Coppola JT, Mindrescu C, Staniloae CS. Pioglitazone increases adiponectin levels in nondiabetic patients with coronary artery disease. Coron Artery Dis. 2008;19(5):349-53.
60. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Investig. 1996;97(11):2601-10.
61. de Kreutzenberg SV, Crepaldi C, Marchetto S, Calo L, Tiengo A, Del Prato S, et al. Plasma free fatty acids and endothelium-dependent vasodilation: effect of chain-length and cyclooxygenase inhibition. J Clin Endocrinol Metab. 2000;85(2):793-8. (Pubitemid 32273670)
62. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Investig. 1997;100(5):1230-9. (Pubitemid 27386309)
63. de Jongh RT, Serne EH, Ijzerman RG, de Vries G, Stehouwer CD. Free fatty acid levels modulate microvascular function: relevance for obesity-associated insulin resistance, hypertension, and microangiopathy. Diabetes. 2004;53(11):2873-82. (Pubitemid 39425913)
64. Lovisolo PP, Briatico-Vangosa G, Orsini G, Ronchi R, Angelucci R, Valzelli G. Pharmacological profile of a new anti-lipolytic agent: 5-methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox) (1) I - Mechanism of action. Pharmacol Res Commun. 1981;13(2):151-61. (Pubitemid 11183346)
65. Avogaro A, Miola M, Favaro A, Gottardo L, Pacini G, Manzato E, et al. Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. Eur J Clin Investig. 2001;31(7):603-9. (Pubitemid 32642891)
66. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008;101(8A):20B-6B.
67. Lukasova M, Hanson J, Tunaru S, Offermanns S. Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials. Trends Pharmacol Sci. 2011;32(12):700-7.
68. Andrews TC, Whitney EJ, Green G, Kalenian R, Personius BE. Effect of gemfibrozil +/- niacin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl. Am J Cardiol. 1997;80(7):831-5. (Pubitemid 27459153)
69. Warnholtz A, Wild P, Ostad MA, Elsner V, Stieber F, Schinzel R, et al. Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study. Atherosclerosis. 2009;204(1):216-21.
70. Johnston P, Hollenbeck C, Sheu W, Chen YD, Reaven GM. Acute changes in plasma non-esterified fatty acid concentration do not change hepatic glucose production in people with type 2 diabetes. Diabet Med J Br Diabet Assoc. 1990;7(10):871-5.
71. Alvarsson M, Grill V. Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin responders. Scand J Clin Lab Investig. 1996;56(6):563-70. (Pubitemid 26342641)
72. Kelly JJ, Lawson JA, Campbell LV, Storlien LH, Jenkins AB, Whitworth JA, et al. Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects. J Hum Hypertens. 2000;14(9):567-72.
73. Shearer GC, Savinova OV, Harris WS. Fish oil - how does it reduce plasma triglycerides? Biochim Biophys Acta. 2012;1821(5):843-51.
74. Rivellese AA, Maffettone A, Iovine C, Di Marino L, Annuzzi G, Mancini M, et al. Long-term effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertriglyceridemia. Diabetes Care. 1996;19(11):1207-13.
75. Muurling M, Mensink RP, Pijl H, Romijn JA, Havekes LM, Voshol PJ. A fish oil diet does not reverse insulin resistance despite decreased adipose tissue TNF-alpha protein concentration in ApoE-3*Leiden mice. J Nutr. 2003;133(11):3350-5. (Pubitemid 37409458)
76. McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR, et al. Dietary fish oil augments nitric oxide production or release in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1993;36(1):33-8. (Pubitemid 23018332)
77. Mori TA, Watts GF, Burke V, Hilme E, Puddey IB, Beilin LJ. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation. 2000;102(11):1264-9.
78. Rizza S, Tesauro M, Cardillo C, Galli A, Iantorno M, Gigli F, et al. Fish oil supplementation improves endothelial function in normoglycemic offspring of patients with type 2 diabetes. Atherosclerosis. 2009;206(2):569-74.
79. Eckel RH, Wassef M, Chait A, Sobel B, Barrett E, King G, et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. Circulation. 2002;105(18):e138-43.
80. Natali A, Toschi E, Baldeweg S, Ciociaro D, Favilla S, Sacca L, et al. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes. 2006;55(4):1133-40. (Pubitemid 44100192)
81. Nystrom T, Nygren A, Sjoholm A. Increased levels of tumour necrosis factor-alpha (TNF-alpha) in patients with Type II diabetes mellitus after myocardial infarction are related to endothelial dysfunction. Clin Sci. 2006;110(6):673-81. (Pubitemid 43844737)
82. Gokulakrishnan K, Deepa R, Mohan V. Association of high sensitivity C-reactive protein (hsCRP) and tumour necrosis factor-alpha (TNF-alpha) with carotid intimal medial thickness in subjects with different grades of glucose intolerance-the Chennai Urban Rural Epidemiology Study (CURES-31). Clin Biochem. 2008;41(7-8):480-5.
83. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87-91. (Pubitemid 23036092)
84. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes. 1994;43(11):1271-8.
85. Patel JN, Jager A, Schalkwijk C, Corder R, Douthwaite JA, Yudkin JS, et al. Effects of tumour necrosis factor-alpha in the human forearm: blood flow and endothelin-1 release. Clin Sci. 2002;103(4):409-15. (Pubitemid 35193246)
86. Rask-Madsen C, Dominguez H, Ihlemann N, Hermann T, Kober L, Torp-Pedersen C. Tumor necrosis factor-alpha inhibits insulin's stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans. Circulation. 2003;108(15):1815-21. (Pubitemid 37296090)
87. Kim F, Tysseling KA, Rice J, Pham M, Haji L, Gallis BM, et al. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. Arterioscler Thromb Vasc Biol. 2005;25(5):989-94. (Pubitemid 40627844)
88. Harvey KA, Walker CL, Pavlina TM, Xu Z, Zaloga GP, Siddiqui RA. Long-chain saturated fatty acids induce pro-inflammatory responses and impact endothelial cell growth. Clin Nutr. 2010;29(4):492-500.
89. Nitenberg A, Cosson E, Pham I. Postprandial endothelial dysfunction: role of glucose, lipids and insulin. Diabete Metab. 2006;32(Spec No2):2S28-33. (Pubitemid 47216113)
90. Lalla E, Lamster IB, Stern DM, Schmidt AM. Receptor for advanced glycation end products, inflammation, and accelerated periodontal disease in diabetes: mechanisms and insights into therapeutic modalities. Ann Periodontol Am Acad Periodontol. 2001;6(1):113-8.
91. Dominguez H, Storgaard H, Rask-Madsen C, Steffen Hermann T, Ihlemann N, Baunbjerg Nielsen D, et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res. 2005;42(6):517-25. (Pubitemid 41527607)
92. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006;24(1):83-6.
93. Koutroubakis IE, Oustamanolakis P, Malliaraki N, Karmiris K, Chalkiadakis I, Ganotakis E, et al. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2009;21(3):283-8.
94. Marra M, Campanati A, Testa R, Sirolla C, Bonfigli AR, Franceschi C, et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol. 2007;20(4):731-6.
95. Stanley TL, Zanni MV, Johnsen S, Rasheed S, Makimura H, Lee H, et al. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab. 2011;96(1):E146-50.
96. Yazdani-Biuki B, Stelzl H, Brezinschek HP, Hermann J, Mueller T, Krippl P, et al. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab. Eur J Clin Investig. 2004;34(9):641-2. (Pubitemid 39331479)
97. Di Rocco P, Manco M, Rosa G, Greco AV, Mingrone G. Lowered tumor necrosis factor receptors, but not increased insulin sensitivity, with infliximab. Obes Res. 2004;12(4):734-9. (Pubitemid 41132519)
98. Ferraz-Amaro I, Arce-Franco M, Muniz J, Lopez-Fernandez J, Hernandez-Hernandez V, Franco A, et al. Systemic blockade of TNF-alpha does not improve insulin resistance in humans. Horm Metab Res Horm Stoffwechselforschung Horm Metab. 2011;43(11):801-8.
99. Martinez-Abundis E, Reynoso-von Drateln C, Hernandez-Salazar E, Gonzalez-Ortiz M. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res. 2007;299(9):461-5. (Pubitemid 47546924)
100. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation. 2002;106(17):2184-7. (Pubitemid 35222210)
101. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Gonzalez-Gay MA. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum. 2004;51(3):447-50. (Pubitemid 38725146)
102. Cardillo C, Schinzari F, Mores N, Mettimano M, Melina D, Zoli A, et al. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis. Clin Pharmacol Ther. 2006;80(3):275-81. (Pubitemid 44313905)
103. Bosello S, Santoliquido A, Zoli A, Di Campli C, Flore R, Tondi P, et al. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clin Rheumatol. 2008;27(7):833-9.
104. Schinzari F, Armuzzi A, De Pascalis B, Mores N, Tesauro M, Melina D, et al. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease. Clin Pharmacol Ther. 2008;83(1):70-6.
105. Wascher TC, Lindeman JH, Sourij H, Kooistra T, Pacini G, Roden M. Chronic TNF-alpha neutralization does not improve insulin resistance or endothelial function in "healthy" men with metabolic syndrome. Mol Med. 2011;17(3-4):189-93.
106. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Investig. 2006;116(7):1793-801.
107. Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008;31(2):289-94. (Pubitemid 351213338)
108. Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J, et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci. 2008;1(1):36-43.
109. Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2010;152(6):346-57.
110. Gupta SK, Johnson RM, Saha C, Mather KJ, Greenwald ML, Waltz JS, et al. Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study. AIDS. 2008;22(5):653-5. (Pubitemid 351640600)
111. Pierce GL, Lesniewski LA, Lawson BR, Beske SD, Seals DR. Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans. Circulation. 2009;119(9):1284-92.
112. Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 2000;1498(2-3):99-111.
113. Rashid G, Benchetrit S, Fishman D, Bernheim J. Effect of advanced glycation end-products on gene expression and synthesis of TNF-alpha and endothelial nitric oxide synthase by endothelial cells. Kidney Int. 2004;66(3):1099-106. (Pubitemid 39121015)
114. Soro-Paavonen A, Zhang WZ, Venardos K, Coughlan MT, Harris E, Tong DC, et al. Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase. J Hypertens. 2010;28(4):780-8.
115. van Poppel PC, Netea MG, Smits P, Tack CJ. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care. 2011;34(9):2072-7.
116. Matsui T, Yamagishi S, Ueda S, Nakamura K, Imaizumi T, Takeuchi M, et al. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res. 2007;35(4):482-9. (Pubitemid 47261110)
117. Freidja ML, Tarhouni K, Toutain B, Fassot C, Loufrani L, Henrion D. The AGE-breaker ALT-711 restores high blood flow-dependent remodeling in mesenteric resistance arteries in a rat model of type 2 diabetes. Diabetes. 2012;61(6):1562-72.
118. Kranstuber AL, Del Rio C, Biesiadecki BJ, Hamlin RL, Ottobre J, Gyorke S, et al. Advanced glycation end product cross-link breaker attenuates diabetes-induced cardiac dysfunction by improving sarcoplasmic reticulum calcium handling. Front Physiol. 2012;3:292.
119. Hartog JW, Willemsen S, van Veldhuisen DJ, Posma JL, van Wijk LM, Hummel YM, et al. Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Hear Fail. 2011;13(8):899-908.
120. Zieman SJ, Melenovsky V, Clattenburg L, Corretti MC, Capriotti A, Gerstenblith G, et al. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens. 2007;25(3):577-83. (Pubitemid 46213796)
121. Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, Gotting C, et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care. 2006;29(9):2064-71. (Pubitemid 44871188)
122. Higashi Y, Oshima T, Sasaki N, Ishioka N, Nakano Y, Ozono R, et al. Relationship between insulin resistance and endothelium-dependent vascular relaxation in patients with essential hypertension. Hypertension. 1997;29(1 Pt 2):280-5. (Pubitemid 27074056)
123. Tooke J. The association between insulin resistance and endotheliopathy. Diabetes Obes Metab. 1999;1 Suppl 1:S17-22.
124. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Antihypertensive drugs and reversing of endothelial dysfunction in hypertension. Curr Hypertens Rep. 2000;2(1):64-70.
125. Tezcan H, Yavuz D, Toprak A, Akpinar I, Koc M, Deyneli O, et al. Effect of angiotensin-converting enzyme inhibition on endothelial function and insulin sensitivity in hypertensive patients. J Renin-Angiotensin-Aldosterone Syst JRAAS. 2003;4(2):119-23. (Pubitemid 36790184)
126. Yavuz D, Koc M, Toprak A, Akpinar I, Velioglu A, Deyneli O, et al. Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients. J Renin-Angiotensin-Aldosterone Syst JRAAS. 2003;4(3):197-203. (Pubitemid 37407169)
127. Tomiyama H, Yambe M, Yamada J, Motobe K, Koji Y, Yoshida M, et al. Discrepancy between improvement of insulin sensitivity and that of arterial endothelial function in patients receiving antihypertensive medication. J Hypertens. 2007;25(4):883-9. (Pubitemid 46398885)
128. Chou CL, Pang CY, Lee TJ, Fang TC. Direct renin inhibitor prevents and ameliorates insulin resistance, aortic endothelial dysfunction and vascular remodeling in fructose-fed hypertensive rats. Hypertens Res Off J Jpn Soc Hypertens. 2012. doi: 10.1038/hr.2012.124.
129. Lteif AA, Chisholm RL, Gilbert K, Considine RV, Mather KJ. Effects of losartan on whole body, skeletal muscle and vascular insulin responses in obesity/insulin resistance without hypertension. Diabetes Obes Metab. 2012;14(3):254-61.
130. Hermann TS, Li W, Dominguez H, Ihlemann N, Rask-Madsen C, Major-Pedersen A, et al. Quinapril treatment increases insulin-stimulated endothelial function and adiponectin gene expression in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91(3):1001-8. (Pubitemid 43357772)
131. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117-25.
132. Economides PA, Caselli A, Tiani E, Khaodhiar L, Horton ES, Veves A. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab. 2004;89(2):740-7. (Pubitemid 38269887)
133. Beishuizen ED, Tamsma JT, Jukema JW, van de Ree MA, van der Vijver JC, Meinders AE, et al. The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease. Diabetes Care. 2005;28(7):1668-74. (Pubitemid 41340907)
134. Koh KK, Quon MJ, Han SH, Lee Y, Ahn JY, Kim SJ, et al. Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care. 2008;31(4):776-82.
135. Kater AL, Batista MC, Ferreira SR. Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe. Metab Clin Exp. 2010;59(6):921-6.
136. Paradisi G, Bracaglia M, Basile F, Di'Ipolito S, Di Nicuolo F, Ianniello F, et al. Effect of pravastatin on endothelial function and endothelial progenitor cells in healthy postmenopausal women. Clin Exp Obstet Gynecol. 2012;39(2):153-9.
137. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med. 2012;172(2):144-52.
138. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565-71.
139. Waters DD, Ho JE, Boekholdt SM, Demicco DA, Kastelein JJ, Messig M, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol. 2012;61(2):148-52.
140. Zaharan NL, Williams D, Bennett K. Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol. 2012. doi: 10.1111/j.1365-2125.2012.04403.x.
141. Vanhoutte PM. Endothelium and control of vascular function. State of the Art lecture. Hypertension. 1989;13(6 Pt 2):658-67. (Pubitemid 19157952)
142. Luscher TF, Yang Z, Tschudi M, von Segesser L, Stulz P, Boulanger C, et al. Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins. Circ Res. 1990;66(4):1088-94. (Pubitemid 20126439)
143. Park JY, Takahara N, Gabriele A, Chou E, Naruse K, Suzuma K, et al. Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes. 2000;49(7):1239-48. (Pubitemid 30439101)
144. Piatti PM, Monti LD, Conti M, Baruffaldi L, Galli L, Phan CV, et al. Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. Diabetes. 1996;45(3):316-21. (Pubitemid 26069045)
145. Seljeflot I, Moan A, Aspelin T, Tonnessen T, Kjeldsen SE, Arnesen H. Circulating levels of endothelin-1 during acute hyperinsulinemia in patients with essential hypertension treated with type 1 angiotensin receptor antagonist or placebo. Metab Clin Exp. 1998;47(3):292-6. (Pubitemid 28108776)
146. Guo JP, Siegfried MR, Lefer AM. Endothelial preserving actions of a nitric oxide donor in carotid arterial intimal injury. Methods Find Exp Clin Pharmacol. 1994;16(5):347-54. (Pubitemid 24214174)
147. Liu GL, Christopher TA, Lopez BL, Gao F, Guo Y, Gao E, et al. SP/W-5186, A cysteine-containing nitric oxide donor, attenuates postischemic myocardial injury. J Pharmacol Exp Ther. 1998;287(2):527-37. (Pubitemid 29133650)
148. Rossoni G, Manfredi B, Del Soldato P, Berti F. NCX 4016, a nitric oxide-releasing aspirin, modulates adrenergic vasoconstriction in the perfused rat tail artery. Br J Pharmacol. 2002;137(2):229-36.
149. Durante W, Johnson FK, Johnson RA. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol. 2007;34(9):906-11. (Pubitemid 47083958)
150. Shemyakin A, Kovamees O, Rafnsson A, Bohm F, Svenarud P, Settergren M, et al. Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes. Circulation. 2012;126(25):2943-50.
151. Heitzer T, Krohn K, Albers S, Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia. 2000;43(11):1435-8.
152. Meininger CJ, Cai S, Parker JL, Channon KM, Kelly KA, Becker EJ, et al. GTP cyclohydrolase I gene transfer reverses tetrahydrobiopterin deficiency and increases nitric oxide synthesis in endothelial cells and isolated vessels from diabetic rats. FASEB J Off Publ Fed Am Soc Exp Biol. 2004;18(15):1900-2. (Pubitemid 39602277)
153. Nystrom T, Nygren A, Sjoholm A. Tetrahydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease. Am J Physiol Endocrinol Metab. 2004;287(5):E919-25. (Pubitemid 39382928)
154. Fard A, Tuck CH, Donis JA, Sciacca R, Di Tullio MR, Wu HD, et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol. 2000;20(9):2039-44.
155. Toutouzas K, Riga M, Stefanadi E, Stefanadis C. Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance. Horm Metab Res Horm Stoffwechselforschung Horm Metab. 2008;40(9):655-9.
156. Sciacqua A, Grillo N, Quero M, Sesti G, Perticone F. Asymmetric dimethylarginine plasma levels and endothelial function in newly diagnosed type 2 diabetic patients. Int J Mol Sci. 2012;13(11):13804-15.
157. Tang WJ, Hu CP, Chen MF, Deng PY, Li YJ. Epigallocatechin gallate preserves endothelial function by reducing the endogenous nitric oxide synthase inhibitor level. Can J Physiol Pharmacol. 2006;84(2):163-71. (Pubitemid 43901424)
158. Yang TL, Chen MF, Xia X, Luo BL, Li YJ. Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia. Eur J Clin Pharmacol. 2006;62(3):179-84. (Pubitemid 43357575)
159. Tomiyama H, Yamada J, Koji Y, Shiina K, Yoshida M, Yamashina A. Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels. Am J Hypertens. 2007;20(12):1305-11. (Pubitemid 350151686)
160. Young JM, Strey CH, George PM, Florkowski CM, Sies CW, Frampton CM, et al. Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with non-ischaemic heart failure. Eur J Hear Fail. 2008;10(5):463-6.
161. Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res. 2007;19(2):200-7. (Pubitemid 46340840)
162. Aversa A, Vitale C, Volterrani M, Fabbri A, Spera G, Fini M, et al. Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. Diabet Med J Br Diabet Assoc. 2008;25(1):37-44.
163. Yamashiro K, Milsom AB, Duchene J, Panayiotou C, Urabe T, Hattori N, et al. Alterations in nitric oxide and endothelin-1 bioactivity underlie cerebrovascular dysfunction in ApoE-deficient mice. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 2010;30(8):1494-503.
164. Mather KJ, Mirzamohammadi B, Lteif A, Steinberg HO, Baron AD. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes. 2002;51(12):3517-23. (Pubitemid 35403459)
165. Shemyakin A, Bohm F, Wagner H, Efendic S, Bavenholm P, Pernow J. Enhanced endothelium-dependent vasodilatation by dual endothelin receptor blockade in individuals with insulin resistance. J Cardiovasc Pharmacol. 2006;47(3):385-90. (Pubitemid 44309691)
166. Rafnsson A, Bohm F, Settergren M, Gonon A, Brismar K, Pernow J. The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial. Diabetologia. 2012;55(3):600-7.
167. Miller AW, Tulbert C, Puskar M, Busija DW. Enhanced endothelin activity prevents vasodilation to insulin in insulin resistance. Hypertension. 2002;40(1):78-82. (Pubitemid 34755983)
168. Ahlborg G, Shemyakin A, Bohm F, Gonon A, Pernow J. Dual endothelin receptor blockade acutely improves insulin sensitivity in obese patients with insulin resistance and coronary artery disease. Diabetes Care. 2007;30(3):591-6. (Pubitemid 46354339)
169. Lteif A, Vaishnava P, Baron AD, Mather KJ. Endothelin limits insulin action in obese/insulin-resistant humans. Diabetes. 2007;56(3):728-34. (Pubitemid 46348477)
170. Lorenz M, Wessler S, Follmann E, Michaelis W, Dusterhoft T, Baumann G, et al. A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation. J Biol Chem. 2004;279(7):6190-5. (Pubitemid 38220652)
171. Kim JA, Formoso G, Li Y, Potenza MA, Marasciulo FL, Montagnani M, et al. Epigallocatechin gallate, a green tea polyphenol, mediates NO-dependent vasodilation using signaling pathways in vascular endothelium requiring reactive oxygen species and Fyn. J Biol Chem. 2007;282(18):13736-45. (Pubitemid 47100559)
172. Potenza MA, Marasciulo FL, Tarquinio M, Tiravanti E, Colantuono G, Federici A, et al. EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR. Am J Physiol Endocrinol Metab. 2007;292(5):E1378-87. (Pubitemid 46684607)
173. Kim W, Jeong MH, Cho SH, Yun JH, Chae HJ, Ahn YK, et al. Effect of green tea consumption on endothelial function and circulating endothelial progenitor cells in chronic smokers. Circ J Off J Jpn Circ Soc. 2006;70(8):1052-7. (Pubitemid 44161745)
174. Alexopoulos N, Vlachopoulos C, Aznaouridis K, Baou K, Vasiliadou C, Pietri P, et al. The acute effect of green tea consumption on endothelial function in healthy individuals. Eur J Cardiovasc Prev Rehabil Off J Eur Soc Cardiol Work Group Epidemiol Prev Card Rehabil Exerc Physiol. 2008;15(3):300-5.
175. Miller RJ, Jackson KG, Dadd T, Mayes AE, Brown AL, Minihane AM. The impact of the catechol-O-methyltransferase genotype on the acute responsiveness of vascular reactivity to a green tea extract. Br J Nutr. 2011;105(8):1138-44.
176. Formoso G, Chen H, Kim JA, Montagnani M, Consoli A, Quon MJ. Dehydroepiandrosterone mimics acute actions of insulin to stimulate production of both nitric oxide and endothelin 1 via distinct phosphatidylinositol 3-kinase- and mitogen-activated protein kinase-dependent pathways in vascular endothelium. Mol Endocrinol. 2006;20(5):1153-63.
177. Kawano H, Yasue H, Kitagawa A, Hirai N, Yoshida T, Soejima H, et al. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab. 2003;88(7):3190-5. (Pubitemid 36877493)
178. Mieczkowska J, Mosiewicz J, Sak J, Grzybowski A, Terlecki P, Barud W, et al. Effects of cigarette smoking, metabolic syndrome and dehydroepiandrosterone deficiency on intima-media thickness and endothelial function in hypertensive postmenopausal women. Med Sci Monit Int Med J Exp Clin Res. 2012;18(4):CR225-34.
179. Dagre A, Lekakis J, Mihas C, Protogerou A, Thalassinou L, Tryfonopoulos D, et al. Association of dehydroepiandrosterone-sulfate with endothelial function in young women with polycystic ovary syndrome. Eur J Endocrinol Eur Fed Endocr Soc. 2006;154(6):883-90. (Pubitemid 43997728)
180. Novakovic A, Gojkovic-Bukarica L, Peric M, Nezic D, Djukanovic B, Markovic-Lipkovski J, et al. The mechanism of endothelium-independent relaxation induced by the wine polyphenol resveratrol in human internal mammary artery. J Pharmacol Sci. 2006;101(1):85-90. (Pubitemid 43765339)
181. Wallerath T, Deckert G, Ternes T, Anderson H, Li H, Witte K, et al. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation. 2002;106(13):1652-8.
182. Lopez-Sepulveda R, Gomez-Guzman M, Zarzuelo MJ, Romero M, Sanchez M, Quintela AM, et al. Red wine polyphenols prevent endothelial dysfunction induced by endothelin-1 in rat aorta: role of NADPH oxidase. Clin Sci. 2011;120(8):321-33.
183. Nicholson SK, Tucker GA, Brameld JM. Physiological concentrations of dietary polyphenols regulate vascular endothelial cell expression of genes important in cardiovascular health. Br J Nutr. 2010;103(10):1398-403.
184. Fujitaka K, Otani H, Jo F, Jo H, Nomura E, Iwasaki M, et al. Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr Res. 2011;31(11):842-7.
185. Wong RH, Howe PR, Buckley JD, Coates AM, Kunz I, Berry NM. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis NMCD. 2011;21(11):851-6.
186. Shantikumar S, Caporali A, Emanueli C. Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc Res. 2012;93(4):583-93.
187. Zhang MX, Ou H, Shen YH, Wang J, Coselli J, Wang XL. Regulation of endothelial nitric oxide synthase by small RNA. Proc Natl Acad Sci U S A. 2005;102(47):16967-72. (Pubitemid 41692667)
188. Dickhout JG, Hossain GS, Pozza LM, Zhou J, Lhotak S, Austin RC. Peroxynitrite causes endoplasmic reticulum stress and apoptosis in human vascular endothelium: implications in atherogenesis. Arterioscler Thromb Vasc Biol. 2005;25(12):2623-9. (Pubitemid 43732288)
189. Sheikh-Ali M, Sultan S, Alamir AR, Haas MJ, Mooradian AD. Hyperglycemia-induced endoplasmic reticulum stress in endothelial cells. Nutrition. 2010;26(11-12):1146-50.
190. LaRocca TJ, Henson GD, Thorburn A, Sindler AL, Pierce GL, Seals DR. Translational evidence that impaired autophagy contributes to arterial ageing. J Physiol. 2012;590(Pt 14):3305-16.
191. Zhang YL, Cao YJ, Zhang X, Liu HH, Tong T, Xiao GD, et al. The autophagy-lysosome pathway: a novel mechanism involved in the processing of oxidized LDL in human vascular endothelial cells. Biochem Biophys Res Commun. 2010;394(2):377-82.
192. Finan B, Yang B, Ottaway N, Stemmer K, Muller TD, Yi CX, et al. Targeted estrogen delivery reverses the metabolic syndrome. Nat Med. 2012;18(12):1847-56.
193. Haltia LT, Savontaus E, Vahlberg T, Rinne JO, Kaasinen V. Acute hormonal changes following intravenous glucose challenge in lean and obese human subjects. Scand J Clin Lab Investig. 2010;70(4):275-80.
194. Small CJ, Bloom SR. Gut hormones as peripheral anti obesity targets. Curr Drug Targets CNS Neurol Disord. 2004;3(5):379-88. (Pubitemid 39545296)